泽璟制药-U
(688266)
| 流通市值：262.25亿 | | | 总市值：262.25亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,102,866,553.5 | 2,153,678,920.77 | 2,134,543,569.13 | 2,320,274,300.16 |
| 应收票据及应收账款 | 137,742,821.24 | 143,628,405.6 | 132,638,815.48 | 130,880,379.36 |
| 其中：应收票据 | 324,131.6 | 324,131.6 | - | - |
| 应收账款 | 137,418,689.64 | 143,304,274 | 132,638,815.48 | 130,880,379.36 |
| 预付款项 | 40,584,719.96 | 41,281,442.35 | 56,167,118.21 | 44,908,331.29 |
| 其他应收款合计 | 9,621,709.34 | 9,380,983.92 | 9,531,046.62 | 9,359,639.62 |
| 存货 | 167,491,327.54 | 182,861,135.29 | 160,289,459.88 | 141,123,246.36 |
| 其他流动资产 | 4,556,024.47 | 4,567,204.57 | 3,004,080.8 | 2,962,349.27 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,496,560,281.49 | 2,575,898,809.8 | 2,565,243,592.54 | 2,705,741,942.97 |
| 非流动资产: | | | | |
| 其他权益工具投资 | - | - | 5,987,768.53 | 5,987,768.53 |
| 固定资产 | 199,387,144.12 | 205,300,520.51 | 195,613,234.99 | 107,293,300.68 |
| 在建工程 | 127,053,501.11 | 123,471,414.28 | 74,906,160.45 | 146,906,382.55 |
| 使用权资产 | 25,167,656.2 | 34,655,845.75 | 37,045,286.83 | 39,645,470.38 |
| 无形资产 | 45,097,791.62 | 50,010,842.64 | 54,142,400.64 | 59,515,174.85 |
| 长期待摊费用 | 10,231,304.37 | 11,393,549.07 | 27,036,524.79 | 28,748,014.81 |
| 其他非流动资产 | 14,326,202 | 3,883,301.93 | 7,172,941.23 | 5,824,970.31 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 421,263,599.42 | 428,715,474.18 | 401,904,317.46 | 393,921,082.11 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,917,823,880.91 | 3,004,614,283.98 | 2,967,147,910 | 3,099,663,025.08 |
| 流动负债: | | | | |
| 短期借款 | 881,534,044.49 | 951,861,764.88 | 882,215,559.32 | 914,209,554.82 |
| 应付票据及应付账款 | 201,586,659.57 | 197,103,446.9 | 152,642,391.77 | 128,855,118.06 |
| 其中：应付票据 | 18,067,154.8 | 10,208,204.8 | 4,498,500 | 4,498,500 |
| 应付账款 | 183,519,504.77 | 186,895,242.1 | 148,143,891.77 | 124,356,618.06 |
| 预收款项 | - | 15,290.52 | 38,226.3 | 61,162.08 |
| 合同负债 | 273,558.2 | - | - | - |
| 应付职工薪酬 | 46,444,944.33 | 68,504,827.25 | 56,082,939.06 | 49,563,037.3 |
| 应交税费 | 36,620,178.49 | 33,445,688.39 | 34,369,359.77 | 36,564,979.79 |
| 其他应付款合计 | 109,082,718.93 | 106,347,910.54 | 177,017,708.57 | 21,790,773.12 |
| 一年内到期的非流动负债 | 49,939,460.63 | 16,166,597.35 | 11,310,603.39 | 13,174,496.86 |
| 其他流动负债 | - | - | - | 4,913,948.01 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,325,481,564.64 | 1,373,445,525.83 | 1,313,676,788.18 | 1,169,133,070.04 |
| 非流动负债: | | | | |
| 长期借款 | 59,812,578.75 | 44,350,969.43 | - | - |
| 租赁负债 | 13,073,221.81 | 26,861,235.3 | 29,539,566.44 | 29,180,256.79 |
| 递延收益 | 8,019,159.7 | 9,201,753.31 | 12,700,103.68 | 14,015,395.15 |
| 递延所得税负债 | 4,688,624.66 | 5,701,419.8 | 6,538,660.02 | 7,647,583.85 |
| 其他非流动负债 | 283,018,868.95 | 292,452,831.19 | 301,886,793.43 | 311,320,755.67 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 368,612,453.87 | 378,568,209.03 | 350,665,123.57 | 362,163,991.46 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,694,094,018.51 | 1,752,013,734.86 | 1,664,341,911.75 | 1,531,297,061.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 264,708,186 | 264,708,186 | 264,708,186 | 264,708,186 |
| 资本公积 | 3,120,645,068.74 | 3,120,366,607.65 | 3,097,275,094.65 | 3,353,448,970.1 |
| 其他综合收益 | -14,335,489.01 | -14,474,378.1 | 18,218,907.37 | -5,664,888.11 |
| 未分配利润 | -2,145,004,719.2 | -2,116,742,484.07 | -2,076,814,691.77 | -2,045,447,779.47 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,226,013,046.53 | 1,253,857,931.48 | 1,303,387,496.25 | 1,567,044,488.52 |
| 少数股东权益 | -2,283,184.13 | -1,257,382.36 | -581,498 | 1,321,475.06 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,223,729,862.4 | 1,252,600,549.12 | 1,302,805,998.25 | 1,568,365,963.58 |
| 负债和股东权益合计 | 2,917,823,880.91 | 3,004,614,283.98 | 2,967,147,910 | 3,099,663,025.08 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |